Home
Categories
EXPLORE
True Crime
Comedy
Society & Culture
Business
Sports
History
News
About Us
Contact Us
Copyright
© 2024 PodJoint
00:00 / 00:00
Sign in

or

Don't have an account?
Sign up
Forgot password
https://is1-ssl.mzstatic.com/image/thumb/Podcasts116/v4/60/30/b4/6030b447-5ec7-bc6f-ce6c-3e793420b15a/mza_9008196538282945191.jpeg/600x600bb.jpg
NPP BrainPod
Springer Nature
71 episodes
1 week ago
BrainPod is the podcast from the journal Neuropsychopharmacology, produced in association with Nature Publishing Group. Join us as we delve into the latest basic and clinical research that advance our understanding of the brain and behavior, featuring highlighted content from a top journal in fields of neuroscience, psychiatry, and pharmacology. For complete access to the original papers and reviews featured in this podcast, subscribe to Neuropsychopharmacology.

Hosted on Acast. See acast.com/privacy for more information.

Show more...
Science
RSS
All content for NPP BrainPod is the property of Springer Nature and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
BrainPod is the podcast from the journal Neuropsychopharmacology, produced in association with Nature Publishing Group. Join us as we delve into the latest basic and clinical research that advance our understanding of the brain and behavior, featuring highlighted content from a top journal in fields of neuroscience, psychiatry, and pharmacology. For complete access to the original papers and reviews featured in this podcast, subscribe to Neuropsychopharmacology.

Hosted on Acast. See acast.com/privacy for more information.

Show more...
Science
https://assets.pippa.io/shows/61b9f3bd1a8cbe2b563cedcd/1674659784850-2ede8148bf53faf1cecfe09ee0fead3a.jpeg
Validation of L-type calcium channel blocker amlodipine as a novel ADHD treatment through cross-species analysis, drug-target Mendelian randomization, and clinical evidence from medical records
NPP BrainPod
9 minutes 41 seconds
5 months ago
Validation of L-type calcium channel blocker amlodipine as a novel ADHD treatment through cross-species analysis, drug-target Mendelian randomization, and clinical evidence from medical records

Attention deficit hyperactivity disorder, or ADHD, is a common condition that, for a lot of people, is difficult to treat. The drugs that exist have a number of adverse side effects, and about 25 percent of patients don’t respond to existing drugs. And so a team of researchers in Iceland, led by Karl Karlsson, professor of biomolecular engineering at Reykjavik University, undertook a number of different steps to narrow in on and then test what the team has determined to be a novel treatment for ADHD, using an existing drug, amlodipine. 


Read the full study here: https://www.nature.com/articles/s41386-025-02062-x


Hosted on Acast. See acast.com/privacy for more information.

NPP BrainPod
BrainPod is the podcast from the journal Neuropsychopharmacology, produced in association with Nature Publishing Group. Join us as we delve into the latest basic and clinical research that advance our understanding of the brain and behavior, featuring highlighted content from a top journal in fields of neuroscience, psychiatry, and pharmacology. For complete access to the original papers and reviews featured in this podcast, subscribe to Neuropsychopharmacology.

Hosted on Acast. See acast.com/privacy for more information.